Eli Lilly Doubles Down on AI: Is the Stock a Buy?

Eli Lilly is partnering with Nvidia to build an AI research lab, doubling down on its AI efforts. The drugmaker has made several AI moves in recent years, including launching TuneLab, a platform for an AI drug-discovery model. While the company's AI-related efforts are unlikely to pay off soon, it seems well-positioned to benefit from the transformation of drug discovery if AI proves effective. There are other reasons to buy the stock, including its strong financial performance and growing dividend.